deltatrials
Recruiting PHASE2 INTERVENTIONAL 3-arm NCT06219941

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)

Sponsor: AstraZeneca

Conditions Biliary Tract Cancer Gastric Cancer Gastroesophageal Junction Cancer Pancreatic Ductal Adenocarcinoma
Interventions 5-Fluorouracil AZD0901 Gemcitabine Irinotecan Leucovorin Nanoliposomal Irinotecan l-leucovorin
Updated 19 times since 2024 Last updated: Feb 11, 2026 Started: Dec 13, 2023 Primary completion: Aug 11, 2026 Completion: Sep 30, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06219941, this PHASE2 trial focuses on Biliary Tract Cancer and Gastric Cancer and remains actively recruiting participants. Sponsored by AstraZeneca, it has been updated 19 times since 2023, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~May 2024 · 30 days · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Nov 2024 · 31 days · monthly snapshot~Nov 2024 – ~Feb 2025 · 3 months · monthly snapshotRecruiting~Feb 2025 – ~Apr 2025 · 59 days · monthly snapshot~Apr 2025 – ~Jun 2025 · 2 months · monthly snapshot~Jun 2025 – ~Jul 2025 · 30 days · monthly snapshot~Jul 2025 – ~Aug 2025 · 31 days · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Dec 2025 · 2 months · monthly snapshot~Dec 2025 – ~Feb 2026 · 2 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshotRecruiting

Change History

19 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting PHASE2

  2. Dec 2025 — Feb 2026 [monthly]

    Recruiting PHASE2

  3. Oct 2025 — Dec 2025 [monthly]

    Recruiting PHASE2

  4. Sep 2025 — Oct 2025 [monthly]

    Recruiting PHASE2

  5. Aug 2025 — Sep 2025 [monthly]

    Recruiting PHASE2

▶ Show 14 earlier versions

  1. Jul 2025 — Aug 2025 [monthly]

    Recruiting PHASE2

  2. Jun 2025 — Jul 2025 [monthly]

    Recruiting PHASE2

  3. Apr 2025 — Jun 2025 [monthly]

    Recruiting PHASE2

  4. Feb 2025 — Apr 2025 [monthly]

    Recruiting PHASE2

  5. Nov 2024 — Feb 2025 [monthly]

    Recruiting PHASE2

  6. Oct 2024 — Nov 2024 [monthly]

    Recruiting PHASE2

  7. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE2

  8. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  9. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE2

  10. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  11. May 2024 — Jun 2024 [monthly]

    Recruiting PHASE2

  12. Apr 2024 — May 2024 [monthly]

    Recruiting PHASE2

  13. Mar 2024 — Apr 2024 [monthly]

    Recruiting PHASE2

  14. Feb 2024 — Mar 2024 [monthly]

    Recruiting PHASE2

    First recorded

Dec 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Bukit Merah, Singapore , Changsha, China , Chengdu, China , Chisinau, Moldova , Chūōku, Japan , Commack, United States , George Town, Malaysia , Glasgow, United Kingdom , Gyeonggi-do, South Korea and 36 more locations